Stephen Hall
YOU?
Author Swipe
View article: Benefit–risk analysis of upadacitinib versus adalimumab in patients with rheumatoid arthritis and higher or lower risk of cardiovascular disease
Benefit–risk analysis of upadacitinib versus adalimumab in patients with rheumatoid arthritis and higher or lower risk of cardiovascular disease Open
Objectives Evaluate the risks and benefits of upadacitinib 15 mg vs adalimumab in rheumatoid arthritis (RA) patients with an inadequate response to methotrexate based on cardiovascular (CV) risk. Methods In SELECT-COMPARE, patients receive…
View article: Efficacy and safety of upadacitinib in patients with rheumatoid arthritis and inadequate response or intolerance to biological treatments: results through 5 years from the SELECT-BEYOND study
Efficacy and safety of upadacitinib in patients with rheumatoid arthritis and inadequate response or intolerance to biological treatments: results through 5 years from the SELECT-BEYOND study Open
Objective To evaluate the efficacy and safety of upadacitinib over 5 years among patients with rheumatoid arthritis (RA) in a long-term extension (LTE) of the SELECT-BEYOND phase 3 trial. Methods Patients refractory to ≥1 biological diseas…
View article: Citizen hydrospatial sciences - To csB or not to csB, that is the question!
Citizen hydrospatial sciences - To csB or not to csB, that is the question! Open
Citizen science, where individuals and interested groups of people contribute to scientific research, has been growing significantly. In the hydrospatial realm, covering everything from the water's surface and column, to its depths, to its…
View article: Tofacitinib efficacy, patient‐reported outcomes and safety in patients with psoriasis and a medical history of psoriatic arthritis: Pooled analysis of two Phase <scp>III</scp> studies
Tofacitinib efficacy, patient‐reported outcomes and safety in patients with psoriasis and a medical history of psoriatic arthritis: Pooled analysis of two Phase <span>III</span> studies Open
Approximately 30% of patients with psoriasis have psoriatic arthritis (PsA).1 Patients with PsA with joint/skin symptoms have worse disease activity/patient-reported outcomes (PROs) than patients with only joint symptoms.2 Tofacitinib is a…
View article: Magnetic resonance imaging RAMRIS‐SAFE score—A low‐risk effective measure of rapid response to therapy in rheumatoid arthritis clinical trials
Magnetic resonance imaging RAMRIS‐SAFE score—A low‐risk effective measure of rapid response to therapy in rheumatoid arthritis clinical trials Open
Aim To assess the rapidity of magnetic resonance imaging (MRI) measured synovitis (as measured by synovial thickening using the RAMRIS‐SAFE score) and bone edema in active rheumatoid arthritis (RA) subjects treated with golimumab. Secondar…
View article: Two-year imaging outcomes from a phase 3 randomized trial of secukinumab in patients with non-radiographic axial spondyloarthritis
Two-year imaging outcomes from a phase 3 randomized trial of secukinumab in patients with non-radiographic axial spondyloarthritis Open
Background Radiographic progression and course of inflammation over 2 years in patients with non-radiographic axial spondyloarthritis (nr-axSpA) from the phase 3, randomized, PREVENT study are reported here. Methods In the PREVENT study, a…
View article: E089 Effect of secukinumab on radiographic progression and inflammation in sacroiliac joints and spine in patients with non-radiographic axial spondyloarthritis: 2-year imaging outcomes from a Phase III randomised trial
E089 Effect of secukinumab on radiographic progression and inflammation in sacroiliac joints and spine in patients with non-radiographic axial spondyloarthritis: 2-year imaging outcomes from a Phase III randomised trial Open
Background/Aims In PREVENT (NCT02696031), secukinumab decreased sacroiliac joints (SIJ) bone marrow oedema (BMO) in patients with non-radiographic axial spondyloarthritis (nr-axSpA) through 52 weeks. We report radiographic progression and …
View article: Certolizumab Pegol Efficacy in Patients With <scp>Non‐Radiographic</scp> Axial Spondyloarthritis Stratified by Baseline <scp>MRI</scp> and <scp>C‐Reactive</scp> Protein Status: An Analysis From the <scp>C‐axSpAnd</scp> Study
Certolizumab Pegol Efficacy in Patients With <span>Non‐Radiographic</span> Axial Spondyloarthritis Stratified by Baseline <span>MRI</span> and <span>C‐Reactive</span> Protein Status: An Analysis From the <span>C‐axSpAnd</span> Study Open
Objective Tumor necrosis factor inhibitors (TNFi) are an effective treatment for non‐radiographic axial spondyloarthritis (nr‐axSpA). To be eligible, however, many authorities require patients with nr‐axSpA to show active sacroiliitis on m…
View article: Inhibition of structural joint damage progression with upadacitinib in rheumatoid arthritis: 1-year outcomes from the SELECT phase 3 program
Inhibition of structural joint damage progression with upadacitinib in rheumatoid arthritis: 1-year outcomes from the SELECT phase 3 program Open
Objectives To evaluate the inhibition of progression of structural joint damage through week 48 in patients with moderately to severely active RA receiving upadacitinib as monotherapy or in combination with MTX. Methods Radiographic progre…
View article: Efficacy and Safety of Ixekizumab in Patients with Psoriatic Arthritis and Inadequate Response to TNF Inhibitors: 3-Year Follow-Up (SPIRIT-P2)
Efficacy and Safety of Ixekizumab in Patients with Psoriatic Arthritis and Inadequate Response to TNF Inhibitors: 3-Year Follow-Up (SPIRIT-P2) Open
ClinicalTrials.gov identifier: NCT02349295.
View article: Improvement of Signs and Symptoms of Nonradiographic Axial Spondyloarthritis in Patients Treated With Secukinumab: Primary Results of a Randomized, Placebo‐Controlled Phase III Study
Improvement of Signs and Symptoms of Nonradiographic Axial Spondyloarthritis in Patients Treated With Secukinumab: Primary Results of a Randomized, Placebo‐Controlled Phase III Study Open
Objective To report the primary (1‐year) results from PREVENT, the first phase III study evaluating secukinumab in patients with active nonradiographic axial spondyloarthritis (SpA). Methods A total of 555 patients were randomized (1:1:1) …
View article: Long‐Term Safety and Tolerability of Apremilast Versus Placebo in Psoriatic Arthritis: A Pooled Safety Analysis of Three Phase III, Randomized, Controlled Trials
Long‐Term Safety and Tolerability of Apremilast Versus Placebo in Psoriatic Arthritis: A Pooled Safety Analysis of Three Phase III, Randomized, Controlled Trials Open
Objective Psoriatic arthritis (PsA) requires long‐term treatment, yet safety concerns and monitoring requirements make maintenance a challenge. This analysis of pooled Psoriatic Arthritis Long‐term Assessment of Clinical Efficacy (PALACE) …
View article: Myopathy secondary to empagliflozin therapy in type 2 diabetes
Myopathy secondary to empagliflozin therapy in type 2 diabetes Open
Summary Sodium/glucose co-transporter 2 (SGLT2) inhibitors are novel oral hypoglycaemic agents that are increasingly used in the management of type 2 diabetes mellitus (T2DM). They are now recommended as second-line pharmacotherapy (in con…
View article: P200 Characterisation of remission in patients with rheumatoid arthritis treated with upadacitinib or comparators
P200 Characterisation of remission in patients with rheumatoid arthritis treated with upadacitinib or comparators Open
Background Across all phase 3 studies, treatment with upadacitinib (UPA), a JAK1-selective inhibitor, was associated with significantly higher remission (REM) rates, compared to placebo (PBO) or active comparators, in RA patients who were …
View article: P242 CZP improves work and household productivity and social participation over 1 year of treatment in patients with non-radiographic axSpA
P242 CZP improves work and household productivity and social participation over 1 year of treatment in patients with non-radiographic axSpA Open
Background Certolizumab pegol (CZP) treatment has been shown to significantly improve work and household productivity and social participation compared to placebo in active non-radiographic axial spondyloarthritis (nr-axSpA) patients up to…
View article: P225 Inhibition of structural joint damage with upadacitinib as monotherapy or in combination with MTX in patrients with RA: one-year outcomes from the select Phase 3 programme
P225 Inhibition of structural joint damage with upadacitinib as monotherapy or in combination with MTX in patrients with RA: one-year outcomes from the select Phase 3 programme Open
Background Long-term prevention of structural joint damage is a key treatment goal in the management of RA. Upadacitinib (UPA), a JAK1-selective inhibitor, inhibited the progression of structural joint damage at 6 months as monotherapy in …
View article: Secukinumab Provides Sustained Improvements in the Signs and Symptoms of Psoriatic Arthritis: Final 5‐year Results from the Phase 3 <scp>FUTURE</scp> 1 Study
Secukinumab Provides Sustained Improvements in the Signs and Symptoms of Psoriatic Arthritis: Final 5‐year Results from the Phase 3 <span>FUTURE</span> 1 Study Open
Objective To report the 5‐year efficacy and safety of secukinumab in the treatment of patients with psoriatic arthritis (PsA) in the FUTURE 1 study ( NCT 01392326). Methods Following the 2‐year core trial, eligible patients receiving subcu…
View article: A Fifty‐Two–Week, Randomized, Placebo‐Controlled Trial of Certolizumab Pegol in Nonradiographic Axial Spondyloarthritis
A Fifty‐Two–Week, Randomized, Placebo‐Controlled Trial of Certolizumab Pegol in Nonradiographic Axial Spondyloarthritis Open
Objective The natural history of nonradiographic axial spondyloarthritis (SpA) is incompletely characterized, and there are concerns that nonsteroidal antiinflammatory drugs provide inadequate disease control in patients with active diseas…
View article: Treatment outcomes in patients with seropositive versus seronegative rheumatoid arthritis in Phase III randomised clinical trials of tofacitinib
Treatment outcomes in patients with seropositive versus seronegative rheumatoid arthritis in Phase III randomised clinical trials of tofacitinib Open
Objectives Tofacitinib is an oral JAK inhibitor for the treatment of rheumatoid arthritis (RA). We examined response to tofacitinib 5 or 10 mg two times a day in patients with seropositive vs seronegative RA. Methods Data were pooled from …
View article: Secukinumab in the treatment of psoriatic arthritis: efficacy and safety results through 3 years from the year 1 extension of the randomised phase III FUTURE 1 trial
Secukinumab in the treatment of psoriatic arthritis: efficacy and safety results through 3 years from the year 1 extension of the randomised phase III FUTURE 1 trial Open
Objective To assess the long-term (3 year) efficacy and safety of secukinumab in patients with active psoriatic arthritis (PsA) in the extension phase of the FUTURE 1 study ( NCT01892436 ). Methods Following the 2-year core trial, eligible…